Compare Domino's Pizza, Inc. (DPZ) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Domino's Pizza, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Domino's Pizza, Inc. trades at $352.8 (market cap $11.82B), while State Street SPDR S&P Biotech ETF trades at $159.11. The key difference: Domino's Pizza, Inc. pays a 2.23% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Domino's Pizza, Inc. nearer its low. Which is the better fit depends on your goals.
| DPZ | XBI | |
|---|---|---|
Market Cap | $11.82B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $467.30 | $164.28 |
52-Week Low | $282.89 | $86.92 |
Enterprise Value | $16.78B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DPZ trades at $353.57, up 1.64% today, with bullish technical signals from moving averages and a consensus analyst price target of $371.67. Recent earnings missed expectations in Q2 2026, but revenue grew to $4.94B in 2025 with a net income margin of 11.86%. The company launched a new individual-size pizza in August 2026 to boost sales, while high debt levels and weak premium pizza demand pose challenges.
The outlook is cautiously optimistic, supported by analyst buy ratings (53.85%) and innovation initiatives, but risks include rising input costs, competitive pressures, and insider selling. Investors should weigh strong cash flow generation against debt sustainability for long-term value.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
